The Company owns the unique HuCAL (Human Combinatorial Antibody Library) technology, comprising several billion different, fully human antibodies. HuCAL allows rapid and automated production of high-affinity antibodies. Its most important feature enables systematic optimization of fully human antibodies to precisely defined specifications.
By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets.
HuCAL is a proven source of antibody drug candidates. The latest version, HuCAL PLATINUM, and its predecessor, HuCAL GOLD, both have set new standards for how the next generation of therapeutic agents is made. Driven by these technologies, the Company’s product pipeline is gaining more and more visibility.
